


TOTAL SYNTHESIS OF (+)-7-DEOXYDAUNOMYCINONE AND (+)-7-DEOXYISODAUNOMYCINONE

Robert D. Gleim, Steven Trenbeath, R. S. D. Mittal and Charles J. Sih*
 School of Pharmacy, University of Wisconsin, Madison, Wisconsin 53706







(Received in USA 28 May 1976; received in UK for publication 9 August 1976)

The anthracycline antibiotics, Daunorubicin¹, 1 and Adriamycin², 2 are established antineoplastic agents used for the clinical treatment of a broad spectrum of human cancers. The lack of an efficient biosynthetic process³ coupled with their therapeutic importance have prompted the investigations of chemical synthesis to alleviate the scarcity of these drugs.^{4,5,6} Recently, we described an effective route⁷ to the tetracyclic anthracyclinone ring system based on an efficient one-step cyclization of the tetrahydronaphthyl esters of 3-methoxy-phthalic acid, catalyzed by BF₃-etherate. We now report the successful adaptation of this approach to allow the synthesis of (+)-7-deoxydaunomycinone, 16 and (+)-7-deoxyisodaunomycinone, 17.



The hydrogen bonded interaction between the C-4 carbonyl and the phenolic proton at C-5 in the dihydroxytetralone, 6, obtained by demethylation of the known dimethyl ether⁸, 5 allowed us to prepare the key ester intermediate, 8 in 77% yield, m.p. 131-133°, NMR (CDCl₃) 12.20 (s, 1H), 7.76 (dd, J₁ = 7.5 Hz, J₂ = 1.4 Hz, 1H), 7.50 (dd, J₁ = J₂ = 7.5 Hz, 1H), 7.32-7.1 (m, 2H), 6.83 (d, J = 9 Hz, 1H), 3.90 (s, 3H), 3.88 (s, 3H), 3.33-2.7 (m, 5H), 2.22 (s, 1H), via regiospecific acylation⁹ of 6 with 2-carbomethoxy-3-methoxy-benzoic acid, 7.



Efforts to catalyze an apparent Fries-rearrangement and subsequent dehydrative cyclization by treating 8 with BF₃-etherate⁷ led to only a small quantity



of tetracyclic compounds. Presumably, the electron withdrawing property of the C-4 carbonyl function deactivates the C-7 position of the dihydroxytetralone portion of the molecule. Similarly, reaction of 9, obtained by hydrogenation (5% Pd/C) of 8, with BF₃-etherate also gave very low yields of tetracyclic products. Therefore, 8 was hydrogenolyzed (Pd/C; HAC:H₂O:HCl; 50:5:1) to afford 10 in 70% yield, m.p. 168.5-170.5°, NMR 7.78 (dd, J₁ = 7.8 Hz, J₂ = 1.2 Hz, 1H), 7.47 (dd, J₁ = J₂ = 7.8 Hz, 1H), 7.19 (dd, J₁ = 7.8 Hz, J₂ = 1.2 Hz, 1H), 6.65 (AB, q, J = 8.7 Hz, ν AB = 18 Hz, 2H), 3.86 (s, 3H), 2.18 (s, 3H), 1.3-3.00 (m, 7H). When 10 was heated with BF₃-etherate at 100° C for 75 minutes, two major components were obtained after chromatography over a silica gel column (chloroform eluent) (40% yield). The faster moving red band (3%) (R_f 0.59¹¹) was assigned the structure 13 as an isomeric mixture, m.p. 121-125° C, NMR δ 13.50, 13.30 (s, 1H each ArOH), 8.0-7.1 (m, 3H), 6.55 (s, 1H), 3.95 (s, 3H), 2.95-2.65 (m, 2H), 2.4-2.1 (m, 4H), m/e 350 (100); 321 (88); 306 (61); 303 (89). It is noteworthy that 13 may serve as an useful precursor to Rhodomycinone¹² and Aklavinone¹³. The second orange component (37%) (R_f 0.43) was further resolved into two compounds, the less polar 14, m.p. 243-245° C, NMR δ 13.78, 13.43 (s, 1H each, ArOH), 8.1-7.2 (m, 3H), 4.08 (s, 3H, OCH₃), 3.2-2.5 (m, 4H), 2.27 (s, 3H,), 2.15 (m, 1H); the more polar 15, m.p. 216-217° C, NMR δ 13.77 (s, 1H), 13.32 (s, 1H), 8.0-7.2 (m, 3H), 4.10 (s, 3H), 3.2-2.5 (m, 4H), 2.27 (s, 3H), 2.17 (m, 1H), in a ratio of 60:40 via preparative tlc (ten developments in CHCl₃).

These results clearly show that this Lewis acid-catalyzed reductive cyclization did not proceed regioselectively as we had hoped. In an attempt to improve the regioselectivity of this cyclization, we prepared 11 (reaction

of 10 with $\text{CH}_3\text{I}/\text{K}_2\text{CO}_3$) and 12 (treating 10 with isobutyl chloroformate) with a view to discriminating the electron densities at C-6 and C-7. Unfortunately, both 11 and 12 reacted slowly in BF_3 -etherate resulting in a complex mixture of products in low yields. Thus, it appears that the phenolic function at C-5 in 10 must remain unprotected for facile cyclization to occur.

1314 $\text{R}_2 = \text{OCH}_3$; $\text{R}_1, \text{R}_3, \text{R}_4 = \text{H}$ 15 $\text{R}_1 = \text{OCH}_3$; $\text{R}_2, \text{R}_3, \text{R}_4 = \text{H}$ 16 $\text{R}_2 = \text{OCH}_3$; $\text{R}_3 = \text{OH}$; $\text{R}_1, \text{R}_4 = \text{H}$ 17 $\text{R}_1 = \text{OCH}_3$; $\text{R}_3 = \text{OH}$; $\text{R}_2, \text{R}_4 = \text{H}$

Introduction of the tertiary hydroxyl group into 14 at C-9 was accomplished via enol acetylation¹⁴ (refluxing Ac_2O , TsOH , 16 hrs), epoxidation (*m*-chloroperbenzoic acid at 25° , 2 hr), followed by alkaline (0.3 N NaOH , $\text{EtOH}:\text{H}_2\text{O}$, 1:1, 1 hr 25°) and acid¹⁵ ($\text{HOAc}:\text{H}_2\text{SO}_4:\text{H}_2\text{O}$) hydrolyses. After silica gel chromatography (CHCl_3 as eluent), (+)-7-deoxydaunomycinone, 16, m.p. $229\text{--}231^\circ$ ¹⁶, NMR 13.78 (s, 1H), 13.38 (s, 1H), 8.1-7.2 (m, 3H), 4.08 (s, 3H), 2.98 (m, 4H), 2.37 (s, 3H), was obtained in 50% overall yield from 14. Using this same sequence of reactions, 15 was transformed into (+)-7-deoxyisodaunomycinone, 17, m.p. $223\text{--}224^\circ$, NMR 13.78 (s, 1H), 13.3 (s, 1H), 8.1-7.2 (m, 3H), 4.08 (s, 3H), 2.98 (m, 4H), 2.36 (s, 3H).

As the conversions of 16 into daunomycinone, 3 and adriamycinone, 4 via functionalization of the C-7 and C-14 positions have already been achieved^{6,17}, this synthetic route provides access to these anthracyclines.

Acknowledgment

We thank Dr. Arcamone for a generous supply of Daunomycin. This research was supported in part by grants from the National Institutes of Health (AM 4874 and AI-11232).

References and Notes

1. J. Bernard, R. Paul, M. Borron, C. Jacquillat and R. Maral, Ed., "Rubidomycin", Springer-Verlag, New York, N.Y., 1969.
2. R. H. Blum, Cancer Chemother. Rep., Part 3, 6, 247 (1975).
3. F. Arcamone, G. Cassinelli, G. Fantini, A. Grein, P. Orezzi, C. Poh and C. Spalla, Biotech. and Bioeng., 11, 1101 (1969).
4. C. M. Wong, R. Schwenk, D. Popien and T. L. Ho, Can. J. Chem., 51, 466 (1973).
5. A. S. Kende, J. Belletire, T. J. Bentley, E. Hume and J. Airey, J. Amer. Chem. Soc., 97, 4425 (1975).
6. A. S. Kende, Y. G. Tsay and J. E. Mills, J. Amer. Chem. Soc., 98, 1967 (1976).
7. D. M. Miller, S. Trenbeath and C. J. Sih, Tetrahedron Lett., in press (1976).
8. C. M. Wong, D. Popien, R. Schwenk and J. TeRaa, Can. J. Chem., 49, 2712 (1971).
9. J. H. Brewster and C. J. Ciotti, J. Amer. Chem. Soc., 72, 6214 (1955).
10. The yields reported are minimal and no efforts were expended in optimizing the reactions. All new compounds afforded satisfactory C, H analyses; mass spectra and nmr spectra are consistent with the assigned structures. IR and NMR (δ) spectra were taken in CDCl_3 solutions and melting points were uncorrected.
11. The chromatographic system consisted of chloroform-acetone (9:1).
12. H. Brockmann, H. Brockmann, Jr. and J. Niemeyer, Tetrahedron Lett., 45, 4719 (1968).
13. D. Tresselt, K. Eckardt and J. Tax, Tetrahedron, 31, 613 (1975).
14. C. Marshall, T. Kritchevsky, S. Lieberman and T. Gallagher, J. Amer. Chem. Soc., 70, 1837 (1948).
15. J. Attenburrow, J. E. Connett, W. Graham, J. F. Oughton, A. C. Ritchie and P. A. Wilkinson, J. Chem. Soc., 4547 (1961).
16. All tetracyclic compounds were recrystallized from glacial acetic acid; (-)-7-deoxydaunomycinone melted at 246-248^o; the infrared spectra of the triacetate derivatives of (+)-16, m.p. 204.5-205^o (EtOAc-hexane) and (-)-16 are superimposable.
17. T. H. Smith, A. N. Fujiwara, D. W. Henry and W. W. Lee, J. Amer. Chem. Soc., 98, 1969 (1976).